The prescribing of psychotropic drugs in mental health services in Trinidad

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 12, Issue 3, 2002, Pages 207-214

  Moore, Shelley ^a,b   Jaime, Lazara K Montane ^a   Maharajh, Hari ^a   Ramtahal, Indar ^a   Reid, Sandra ^a   Ramsewak, Feroza Sircar ^a   Maharaj, Mala ^a  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^b St Ann's Hospital   (Trinidad and Tobago)

Author keywords

Drug therapy; Drug utilization; Mental disorders; Psychotropic drugs; Trinidad and Tobago

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZATROPINE; FLUOXETINE; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; TRIHEXYPHENIDYL;

DRUG PRESCRIBING; HEALTH SERVICES; MENTAL HEALTH;

ADOLESCENT; ADULT; AFRICA; AGE; ARTICLE; CARIBBEAN ISLANDS; ETHNOLOGY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENDER; HEALTH SURVEY; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH SERVICE; MENTAL PATIENT; MORBIDITY; OUTPATIENT; POLYPHARMACY; PRESCRIPTION; TRINIDAD AND TOBAGO;

TRINIDAD AND TOBAGO;

EID: 0036737990     PISSN: 10204989     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1020-49892002000900010     Document Type: Article

References (26)

1. Pincus HA, Tanielian TL, Marcus SC, Olfson M, Zarin DA, Thompson J, et al. Prescribing trends in psychotropic medications: primary care, psychiatry and other medical specialties. JAMA 1998;279(7):526-531.
2. Voirol P, Robert PA, Meister P, Oros L, Baumann P. Psychotropic drug prescription in a psychiatric university hospital. Psychopsychiatry 1999;32(1):29-37.
3. Zucchero FJ, Hogan MJ. Evaluations of drug interactions. St. Louis, Missouri, United States of America: PDS Publishing Co.; 1990.
4. Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990;51 Suppl B:9-12.
5. Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels J, et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 1991;159: 394-398.
6. Montgomery SA. Sertraline in the prevention of depression [letter]. Br J Psychiatry 1992;161: 271-272.
7. Montgomery SA. Efficacy and safety of the selective serotonin reuptake inhibitors in treating depression in elderly patients. Int Clin Psychopharmacol 1998;13 Suppl 5:S49-54.
8. DasGupta K. Treatment of depression in elderly patients: recent advances. Arch Fam Med 1998;7(3):274-280.
9. American Psychiatry Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154:4.
10. Merlis S, Sheppard C, Collins L, Fiorentino D. Polypharmacy in psychiatry: patterns of differential treatment. Am J Psychiatry 1970; 126(11):1647-1651.
11. Rosholm JU, Hallas J, Gram LF. Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in out-patients-a prescription database study. Br J Clin Pharmacol 1994;37(6):533-538.
12. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 1988;145(11):1478.
13. Preskorn SH, Beber JH, Faul JC, Hirschfeld RM. Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry 1990;147(4):532.
14. Westermeyer J. Fluoxetine-induced toxicity: extent and duration. J Clin Pharmacol 1991; 31(4):388-392.
15. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51(3):239-248.
16. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988;43(4):412-419.
17. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ. Pharmacokinetic-pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berl) 1991;104(3):323-327.
18. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52(5):479-486.
19. Spina E, Avenoso A, Pollicino AM, Capurti AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993;15(3):247-250.
20. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50(1): 10-15.
21. Stockley IH. Drug interactions. 3rd edition. London: Blackwell Scientific Publications; 1991.
22. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF). London: BMA and RPSGB; 1998.
23. Davies DM. Textbook of adverse drug reactions. 4th edition. New York: Oxford University Press; 1991.
24. Miller FA, Rampling D. Adverse effects of combined propranolol and chlorpromazine therapy. Am J Psychiatry 1982;139(9):1198-1199.
25. Silver JM, Yudofsky SC, Kogan M, Katz BL. Elevation of thioridazine plasma levels by propranolol. Am J Psychiatry 1986;143(10): 1290-1292.
26. Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999;156(11):1751-1757.